secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eledon Pharmaceuticals, Inc. (ELDN)
CIK:        0001404281
Form:       8-K
Filed at:   2022-03-24T23:59:59+00:00
Accession:  0001564590-22-011680
Event type: earnings
Sentiment:  negative
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eledon Pharma reports FY2021 net loss of $34.5M; cash $84.8M into 2024
----------------------------------------------------------------------

- Net loss for Q4 2021 was $8.8M ($0.59/share); FY2021 net loss $34.5M ($2.33/share).
- R&D expense rose to $23.7M in FY2021 from $6.1M in FY2020, driven by tegoprubart trials.
- Cash and equivalents $84.8M at Dec 31, 2021, down from $114.2M a year earlier.
- Topline Phase 2a tegoprubart data in ALS expected in Q2 2022; kidney, IgAN, islet data in Q4 2022.
- No revenue recorded; net loss widened due to increased clinical development costs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1404281/000156459022011680/0001564590-22-011680-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1404281/000156459022011680/eldn-8k_20220324.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-011680

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer